miltefosine has been researched along with HIV Coinfection in 34 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed." | 7.72 | Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004) |
| " One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1." | 5.51 | AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine." | 5.34 | Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. ( Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J, 2020) |
| "Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions." | 4.83 | Miltefosine: issues to be addressed in the future. ( Berman, J; Bryceson, AD; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA, 2006) |
| " Once treatment for leishmaniasis was started with miltefosine, CD4+ cell count rose above 400/microL." | 3.74 | Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. ( Bestetti, A; Bossolasco, S; Cernuschi, M; Cinque, P; De Bona, A; Gaiera, G; Gianotti, N; Lazzarin, A; Maillard, M, 2008) |
| "Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed." | 3.72 | Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004) |
| "Miltefosine was extracted from DBS samples using a simple method of pretreatment with methanol, resulting in >97% recovery." | 2.82 | Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection. ( Beijnen, JH; Blesson, S; Diro, E; Dorlo, TP; Hailu, A; Hillebrand, MJ; Kip, AE; Mengesha, B; Rosing, H; Schellens, JH, 2016) |
| "Treatment with miltefosine is equally effective as standard SSG treatment in non-HIV-infected men with VL." | 2.72 | A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. ( Assefa, Y; Boots, G; Davidson, RN; Dejenie, A; den Boer, M; Hundie, TB; Mesure, J; Ritmeijer, K, 2006) |
| "Frequent relapses are observed in co-infected HIV who can benefit of a second cycle." | 2.55 | Visceral leishmaniosis in immunocompromised host: an update and literature review. ( Esposito, S; Pagliano, P, 2017) |
| "Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients." | 1.51 | Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. ( Abongomera, C; Adera, C; Battaglioli, T; Ritmeijer, K, 2019) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Miltefosine was used in relapse treatments (50 mg, b." | 1.35 | Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. ( Coelho, F; Marques, N; Meliço-Silvestre, A; Oliveira, J; Sá, R; Saraiva Da Cunha, J, 2008) |
| "We carried out a retrospective and descriptive study of 4 HIV infected patients with relapsing visceral leishmaniasis (VL) seen at 2 tertiary-care hospitals in Spain during the last 6 y, in whom miltefosine was used as a compassionate use treatment at a dosage of 50 mg b." | 1.35 | Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. ( Casquero, A; Fernández-Guerrero, ML; Górgolas, M; Refoyo, E; Troya, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Monge-Maillo, B | 2 |
| Norman, FF | 1 |
| Chamorro-Tojeiro, S | 1 |
| Gioia, F | 1 |
| Pérez-Molina, JA | 1 |
| Chicharro, C | 1 |
| Moreno, J | 1 |
| López-Vélez, R | 3 |
| Burza, S | 3 |
| Mahajan, R | 2 |
| Kazmi, S | 1 |
| Alexander, N | 2 |
| Kumar, D | 2 |
| Kumar, V | 1 |
| Lasry, E | 1 |
| Harshana, A | 1 |
| de Lima Pereira, A | 2 |
| Das, P | 3 |
| Verma, N | 2 |
| Das, VNR | 1 |
| Lal, CS | 2 |
| Rewari, B | 1 |
| Goyal, V | 1 |
| Rijal, S | 1 |
| Alves, F | 3 |
| Gill, N | 1 |
| Pandey, K | 3 |
| Zanelli, G | 1 |
| Rossetti, B | 1 |
| Gagliardini, R | 1 |
| Paglicci, L | 1 |
| Tordini, G | 1 |
| Miracco, C | 1 |
| Aversa, S | 1 |
| Zammarchi, L | 1 |
| Di Muccio, T | 1 |
| Gramiccia, M | 1 |
| Montagnani, F | 1 |
| Adriaensen, W | 1 |
| Cuypers, B | 1 |
| Cordero, CF | 1 |
| Mengasha, B | 1 |
| Blesson, S | 3 |
| Cnops, L | 1 |
| Kaye, PM | 1 |
| Diro, E | 5 |
| van Griensven, J | 3 |
| Kassardjian, AA | 1 |
| Yim, KM | 1 |
| Rabi, S | 1 |
| Liang, TZ | 1 |
| Kim, GH | 1 |
| Ochoa, MT | 1 |
| Sattah, MV | 1 |
| Ahronowitz, IZ | 1 |
| Pagliano, P | 1 |
| Esposito, S | 1 |
| Sundar, S | 3 |
| Singh, A | 2 |
| Abongomera, C | 2 |
| Buyze, J | 1 |
| Stille, K | 1 |
| Ahmed, F | 1 |
| Ritmeijer, K | 5 |
| Edwards, T | 1 |
| Fikre, H | 1 |
| Admassu, H | 1 |
| Kibret, A | 1 |
| Ellis, SJ | 1 |
| Bardonneau, C | 1 |
| Zijlstra, EE | 1 |
| Soipei, P | 1 |
| Mutinda, B | 1 |
| Omollo, R | 1 |
| Kimutai, R | 1 |
| Omwalo, G | 1 |
| Wasunna, M | 1 |
| Tadesse, F | 1 |
| Strub-Wourgaft, N | 1 |
| Hailu, A | 3 |
| Alvar, J | 1 |
| Battaglioli, T | 1 |
| Adera, C | 1 |
| Patole, S | 1 |
| Varghese, GM | 1 |
| Lynen, L | 1 |
| Boelaert, M | 2 |
| Isaakidis, P | 1 |
| Sunyoto, T | 1 |
| Sagili, KD | 1 |
| Lima, MA | 1 |
| Mitra, G | 1 |
| Van Geertruyden, JP | 1 |
| Kip, AE | 1 |
| Rosing, H | 1 |
| Hillebrand, MJ | 1 |
| Mengesha, B | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Dorlo, TP | 1 |
| Costa, S | 1 |
| Machado, M | 1 |
| Cavadas, C | 1 |
| do Céu Sousa, M | 1 |
| Faucher, JF | 1 |
| Morquin, D | 1 |
| Reynes, J | 1 |
| Chirouze, C | 1 |
| Hoen, B | 1 |
| Le Moing, V | 1 |
| Marques, N | 1 |
| Sá, R | 1 |
| Coelho, F | 1 |
| Oliveira, J | 1 |
| Saraiva Da Cunha, J | 1 |
| Meliço-Silvestre, A | 1 |
| Gianotti, N | 1 |
| Maillard, M | 1 |
| Gaiera, G | 1 |
| Bestetti, A | 1 |
| Cernuschi, M | 1 |
| De Bona, A | 1 |
| Lazzarin, A | 1 |
| Cinque, P | 1 |
| Bossolasco, S | 1 |
| Barragán, P | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Vase, MØ | 1 |
| Hellberg, YK | 1 |
| Larsen, CS | 1 |
| Petersen, E | 1 |
| Schaumburg, H | 1 |
| Bendix, K | 1 |
| Ravel, C | 1 |
| Bastien, P | 1 |
| Christensen, M | 1 |
| d'Amore, F | 1 |
| Marty, P | 1 |
| Rosenthal, E | 1 |
| Agarwal, PK | 1 |
| Sindermann, H | 2 |
| Engel, KR | 1 |
| Fischer, C | 1 |
| Bommer, W | 1 |
| Schraner, C | 1 |
| Hasse, B | 1 |
| Hasse, U | 1 |
| Baumann, D | 1 |
| Faeh, A | 1 |
| Burg, G | 1 |
| Grimm, F | 1 |
| Mathis, A | 1 |
| Weber, R | 1 |
| Günthard, HF | 1 |
| Rihl, M | 1 |
| Stoll, M | 1 |
| Ulbricht, K | 1 |
| Bange, FC | 1 |
| Schmidt, RE | 1 |
| Berman, JD | 1 |
| Berman, J | 1 |
| Bryceson, AD | 1 |
| Croft, S | 1 |
| Engel, J | 1 |
| Gutteridge, W | 1 |
| Karbwang, J | 1 |
| Soto, J | 1 |
| Urbina, JA | 1 |
| Dejenie, A | 1 |
| Assefa, Y | 1 |
| Hundie, TB | 1 |
| Mesure, J | 1 |
| Boots, G | 1 |
| den Boer, M | 1 |
| Davidson, RN | 1 |
| Troya, J | 1 |
| Casquero, A | 1 |
| Refoyo, E | 1 |
| Fernández-Guerrero, ML | 1 |
| Górgolas, M | 1 |
| Walochnik, J | 1 |
| Aichelburg, A | 1 |
| Assadian, O | 1 |
| Steuer, A | 1 |
| Visvesvara, G | 1 |
| Vetter, N | 1 |
| Aspöck, H | 1 |
| Chugh, P | 1 |
| Bradel-Tretheway, B | 1 |
| Monteiro-Filho, CM | 1 |
| Planelles, V | 1 |
| Maggirwar, SB | 1 |
| Dewhurst, S | 1 |
| Kim, B | 1 |
| Kumar, N | 1 |
| Das, VN | 1 |
| Sinha, PK | 1 |
| Topno, RK | 1 |
| Bimal, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.[NCT02011958] | Phase 3 | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for miltefosine and HIV Coinfection
| Article | Year |
|---|---|
Diffuse cutaneous leishmaniasis and HIV co-infection: A case report and review of the literature.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Darier Disease; Drug Therapy, Combination; | 2021 |
Visceral leishmaniosis in immunocompromised host: an update and literature review.
Topics: Amphotericin B; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Visceral; Phosphorylc | 2017 |
Chemotherapeutics of visceral leishmaniasis: present and future developments.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; | 2018 |
Visceral Leishmaniasis and HIV coinfection in East Africa.
Topics: Africa, Eastern; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; HIV Infe | 2014 |
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Topics: Administration, Oral; Africa, Eastern; Antiprotozoal Agents; Bangladesh; Coinfection; Drug Therapy, | 2015 |
Treatment of visceral leishmaniasis: a review of current treatment practices.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Developing Countries; HIV Infections; Humans; Leishma | 2002 |
Development of miltefosine for the leishmaniases.
Topics: Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Design; HIV Infections; Humans; L | 2006 |
Miltefosine: issues to be addressed in the future.
Topics: Abnormalities, Drug-Induced; Antiprotozoal Agents; Drug Resistance; Female; Forecasting; HIV Infecti | 2006 |
5 trials available for miltefosine and HIV Coinfection
| Article | Year |
|---|---|
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV | 2022 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression | 2020 |
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; Drug Therapy, Comb | 2019 |
Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Topics: Antiprotozoal Agents; Calibration; Chromatography, Liquid; Coinfection; Dried Blood Spot Testing; Dr | 2016 |
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Comorbidity; Ethiopia; HIV Infections; Human | 2006 |
21 other studies available for miltefosine and HIV Coinfection
| Article | Year |
|---|---|
Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
Topics: Antiprotozoal Agents; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Leishma | 2022 |
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management.
Topics: Coinfection; HIV Infections; Humans; Leishmaniasis, Mucocutaneous; Male; Middle Aged; Phosphorylchol | 2019 |
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; Ethiopia; Femal | 2018 |
Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Ethiopia; HIV Infections; Humans; Leishmania dono | 2019 |
What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
Topics: Antiprotozoal Agents; Clinical Protocols; Communicable Disease Control; Drug Resistance, Microbial; | 2013 |
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coinfection; HIV | 2014 |
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Amphotericin B; Coinfection; D | 2015 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co | 2016 |
Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Topics: Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Immunocompromised Host; Leishmania infant | 2016 |
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Topics: Adult; Antiprotozoal Agents; Chemoprevention; HIV Infections; Humans; Leishmaniasis, Visceral; Male; | 2008 |
Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; CD4 Lymphocyte Count; HIV Infec | 2008 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
Development of splenic marginal zone lymphoma in a HIV-negative patient with visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Bone Marrow; HIV; HIV Infections; Humans; Immunophenotyping; K | 2012 |
Miltefosine for Indian visceral leishmaniasis.
Topics: Antiprotozoal Agents; Hemorrhage; HIV Infections; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2003 |
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Female; HIV Infections; Humans; Immunocompromised | 2004 |
Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Topics: Adult; Antiprotozoal Agents; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Diffuse | 2005 |
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HI | 2006 |
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Bone Marrow; Female; HI | 2008 |
Granulomatous amoebic encephalitis caused by Acanthamoeba amoebae of genotype T2 in a human immunodeficiency virus-negative patient.
Topics: Acanthamoeba; Adult; Amebiasis; Amikacin; Animals; Antiprotozoal Agents; Antitubercular Agents; DNA, | 2008 |
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy.
Topics: Cells, Cultured; Down-Regulation; HIV Infections; HIV-1; Humans; Macrophages; Phosphatidylinositol 3 | 2008 |
HIV infection, visceral leishmaniasis and Guillain-Barré syndrome in the same patient: a case report.
Topics: Adult; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; Guillain-Barre Syndro | 2008 |